We develop antibody-based therapies targeting IL1RAP

See our pipeline

Our goal is to treat cancer as well as inflammatory and autoimmune diseases

See our clinical program

Strong results provide support for our development programs

See our company presentation

2024-10-14 Interview with Redeye

2024-10-14 Interview with Redeye

Interview with CEO Göran Forsberg about the latest results from the phase 1 study of CAN10 and the development of nadunolimab in pancreatic cancer.

Watch the interview in Swedish here

Aktiedagarna

CEO Göran Forsberg presents at Aktiedagarna in Stockholm

Watch the presentation here

Aktiedagarna

2024-06-28 Interview with Redeye

2024-06-28 Interview with Redeye

Interview with CEO Göran Forsberg regarding new results in pancreatic cancer

Watch the interview in Swedish here

Press releases

2024-11-15 (R) Cantargia publishes interim report for third quarter 2024

2024-11-13 (R) Cantargia presents Nomination Committee ahead of 2025 AGM

2024-11-11 Cantargia results showing efficacy of CAN10 in models of myocarditis published in Circulation: Heart Failure

(R) = Regulatory press releases

Analysis

2024-09-09, Redeye analysis of Cantargia

2024-03-18, Redeye analysis of Cantargia

2024-02-21, Redeye analysis of Cantargia

2023-11-13, Redeye analysis of Cantargia

Current corporate presentation

Download the corporate presentation as PDF

Other presentations

2024-11-07, Video, Redeye Investor Forum, Göteborg

2024-10-30, Video, Økonomisk Ugebrev Life Science Investor Conference, Copenhagen (In Swedish)

2024-10-30, Presentation, Økonomisk Ugebrev Life Science Investor Conference, Copenhagen

2024-10-08, Video, LSX Nordic Congress Copenhagen

2024-10-08, Presentation, LSX Nordic Congress Copenhagen